Immunoglobulin replacement in chronic lymphocytic leukaemia

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Infection poses a significant risk of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL) and low-grade B cell lymphomas.
• Impaired antibody production, often presenting as hypogammaglobulinaemia, is a major contributing factor to increased infection risk in these patients.
• Previous studies on immunoglobulin replacement via intramuscular routes yielded inconclusive results.

Purpose of the Study:

• To evaluate the efficacy of regular intravenous immunoglobulin (IVIg) replacement therapy in reducing infections in CLL patients at risk.
• To assess the impact of IVIg on both overall and serious bacterial infections.

Main Methods:

• A multi-center, randomized, double-blind, placebo-controlled study was conducted.
• Eighty-four CLL patients with hypogammaglobulinaemia or a history of significant infections were randomized to receive either IVIg (400 mg/kg) or a saline placebo every 3 weeks for one year.
• A blinded crossover study was also performed on a subset of patients.

Main Results:

• Patients receiving IVIg experienced a 45% reduction in bacterial infections compared to placebo during the study period (p = 0.01).
• A 61% reduction in bacterial infections was observed in patients who completed a full year of IVIg therapy (p = 0.001).
• Serious bacterial infections were significantly less frequent during IVIg treatment months compared to placebo (p = 0.001).

Conclusions:

• Regular IVIg replacement therapy is an effective strategy for reducing bacterial infections in CLL patients at risk.
• IVIg therapy demonstrates a significant benefit in preventing both overall and serious bacterial infections in this patient population.
• The findings support the use of IVIg as a viable treatment option for managing infection risk in CLL and similar hematologic malignancies.